GLPwatch
Correction to Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.
ACS Omega · 2022
Last updated 2026-08-28| Journal | ACS Omega, 2022 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.06 |
| NIH percentile | 5 |
| Molecules | dulaglutide |
Abstract
[This corrects the article DOI: 10.1021/acsomega.0c06326.].
Verbatim abstract via PubMed 35694462 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.